ClinicalTrials.gg
RecruitingNCT05711758PSAMUpdated Mar 2, 2026

Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure

An observational study in Obesity, Obesity, Morbid and Obesity, Primary, sponsored by Christopher C. Thompson, MD, MSc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Christopher C. Thompson, MD, MSc · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Planned enrollment
44th of 63
30 · median 50
Started
2023
with 8 others
Observational
63 of 213
10 open now
Primary completion
2026-12
later than 11 of 34 live
Registered
188th of 213
by date

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 44th largest by planned enrollment of the 63 observational ones that give a count, is one of 9 that started in 2023, is one of 63 observational ones, reaches primary completion later than 11 of the 34 other live ones, and was the 188th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.

Read the detailed description

Obesity, defined as body mass index (BMI) greater than 30 kg/m2 in adults, is affecting 30% of the global population and a significant healthcare burden. [1] Obesity has increased dramatically over the last few decades, with over 650 million adults, or 13% of the world's total adult population, diagnosed with the disease in 2016 - a figure that has nearly tripled since 1975.[1] In the U.S the obesity prevalence for U.S. adults increased from 14.1% to 26.7%, or an 89.9% increase between 1993 and 2008.[1,2,3] As a result, current and potential interventions, and treatment strategies to combat obesity have become more important.

The current treatment of obesity involves multiple strategies with combination of non-pharmacologic, pharmacologic, endoscopic, and surgical interventions. There are several FDA-approved pharmacotherapies for the treatment of obesity such as orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide. For adults with a body mass index (BMI) of 40 kg/m2 or 35 kg/m2 and obesity-related comorbidity, bariatric surgery can be offered. [4, 5] Endoscopic bariatric and metabolic therapies (EBMT) have emerged as an alternative treatment for patients with obesity with a BMI over 30kg/m2 or 27 kg/m2 with an obesity-related comorbidity. The interest in EBMT is growing given their safety, efficacy, and non-invasive nature. Current FDA-cleared devices that can be used for EBMT include intragastric balloons and suturing devices for endoscopic sleeve gastroplasty (ESG). Additionally, a variety of Endo surgical knifes are approved for tissue dissection such as myotomy.

Gastric interventions used to treat obesity work by interfering with gastric accommodation, breakdown and mixing of food, or gastric emptying. Delaying gastric emptying was shown to be a major mechanism of action for both ESG and IGB which is also correlated with weight loss [6].

Antral peristalsis constitutes an important mechanism for gastric emptying. The antrum also serves as a food sensor which needs to be filled to a certain level before food is pumped into the duodenum. [7] Therefore, targeting the antrum is a feasible strategy to delay gastric emptying, induce satiety, and promote weight loss.

In fact, one of the recently FDA-cleared EBMT devices, the Transpyloric Shuttle (Baronova, MA), focuses on inhibiting the antral pump as its primary mechanism of action. This device consists of two interconnected large and small bulbs, positioned in the antrum and duodenum respectively, that cause intermittent obstruction of the pylorus, leading to a delay in gastric emptying (10).

As such, a pylorus sparing antral myotomy (PSAM) with a submucosal tunneling technique was developed. Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The PSAM technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events.

Traditional bariatric surgery is very effective at treating obesity, however, only 1% of eligible patients elect to undergo this treatment option. Additionally, the majority of patients with obesity do not qualify for bariatric surgery. [5] Due to the less invasive nature of PSAM, and relative technical simplicity compared to ESG) this procedure may provide a more widely available and more acceptable treatment option for some patients.

There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.

03

Conditions studied

  • Obesity
  • Obesity, Morbid
  • Obesity, Primary
  • Metabolic Disease
  • Delayed Gastric Emptying Following Procedure

Browse trials for

Keywords

  • Pylorus Sparing Antral Myotomy (PSAM)
  • Gastric physiology
  • Gastric emptying
  • Pylorus-sparing antral myotomy
  • Myotomy
  • Endoscopic Sleeve Gastroplasty (ESG)
  • TransPyloric Shuttle (TPS)
  • Intragastric balloon (IGB)
  • Endoscopic bariatric and metabolic therapies (EBMT)
  • Gut Hormones
  • Gastric Emptying Breath Test
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 30 is below the median of 80 across 311 observational studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Christopher C. Thompson, MD, MSc is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults in the Center for Weight Management and Wellness program at Brigham and Women's Hospital with a BMI >35 kg/m2 who are pre-qualified by their insurance as recommended by their specialist to undergo an endoscopic bariatric procedure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects must be 18-70 years of age
  • eligible for endoscopic and surgical weight loss procedures
  • (BMI) greater than 35 kg/m2
  • Individuals must be in excellent mental health
  • able to understand and sign
  • available to return for all routine follow-up study visits

Exclusion criteria

Exclusion Criteria:

  • untreated H. pylori infection
  • gastroparesis
  • active smoking
  • an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment
  • previous pyloromyotomy or pyloroplasty
  • gastrointestinal obstruction
  • severe coagulopathy
  • esophageal or gastric varices and/or portal hypertensive gastropathy
  • pregnancy or puerperium
  • any inflammatory disease of the gastrointestinal tract (including but not limited to severe (LA Grade C or D) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as Crohn's disease)
  • malignant or premalignant gastric diseases (such as high grade dysplasia, gastric cancer, or GIST)
  • severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)
  • lactation
  • history of gastrointestinal surgery
  • any serious health condition unrelated to their weight that would increase the risk of endoscopy
  • chronic abdominal pain
  • active psychological issues preventing participation in a lifestyle modification program
  • a known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)
  • an inability to provide
  • use of any medication that may interfere with weight loss
  • use of any medication that may interfere with gastric emptying
  • any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • PSAM Treatment Patients with no prior endoscopic bariatric therapies

    Subjects with no prior endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.

    Procedure: PSAM Treatment Patients

  • PSAM Treatment Patients with prior primary endoscopic bariatric therapies

    Subjects with prior primary endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.

    Procedure: PSAM Treatment Patients

  • PSAM Treatment Patients with prior revision endoscopic bariatric therapies

    Subjects with prior revision endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.

    Procedure: PSAM Treatment Patients

Interventions

  • ProcedurePSAM Treatment Patients

    PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.

    Also known as: PSAM

07

What researchers measure

Primary outcomes

  1. Weight change compared to baseline

    Percent total body weight loss

    Time frame: Screening, Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months

  2. Adverse Events

    Changes to health compared to baseline

    Time frame: Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months

  3. Change in tolerability from procedure day to 12 months

    How the subjects feel after the procedure based on pain scale and AE's

    Time frame: Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months

Secondary outcomes

  1. Change in Quality of Life compared to baseline

    Overall quality of life questionnaire

    Time frame: Screening, 1 month, 3 month, 6 month, 9 month, 12 months

  2. Gastric Emptying compared to baseline

    Gastric emptying using a gastric emptying breath test (GEBT)

    Time frame: Screening, 6 months, 12 months

  3. Ghrelin levels compared to baseline

    Laboratory analysis of blood samples to test ghrelin levels

    Time frame: Screening, 6 months, 12 months

  4. Insulin levels compared to baseline

    Laboratory analysis of blood samples to test insulin metabolic profiles

    Time frame: Screening, 6 months, 12 months

  5. HgA1c levels compared to baseline

    Laboratory analysis of blood samples to test HgA1c metabolic profiles

    Time frame: Screening, 6 months, 12 months

  6. Glucose levels compared to baseline

    Laboratory analysis of blood samples to test Glucose metabolic profiles

    Time frame: Screening, 6 months, 12 months

  7. HOMA-IR blood plasma levels compared to baseline

    Laboratory analysis of blood samples to test changes in insulin resistance

    Time frame: Screening, 6 months, 12 months

  8. Physiologic Changes of gastric motility/transit compared to baseline

    Upper GI series comparing pre-procedure barium transit to post-procedure 6 and 12 month time points.

    Time frame: Screening, 6 months, 12 months

  9. Gastric Motility compared to baseline

    Dynamic MRI

    Time frame: Screening, 1 month

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Klem ML, Wing RR, Chang CC, Lang W, McGuire MT, Sugerman HJ, Hutchison SL, Makovich AL, Hill JO. A case-control study of successful maintenance of a substantial weight loss: individuals who lost weight through surgery versus those who lost weight through non-surgical means. Int J Obes Relat Metab Disord. 2000 May;24(5):573-9. doi: 10.1038/sj.ijo.0801199. PubMed 10849578 ↗
  • James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001 Nov;9 Suppl 4:228S-233S. doi: 10.1038/oby.2001.123. PubMed 11707546 ↗
  • Jia H, Lubetkin EI. Obesity-related quality-adjusted life years lost in the U.S. from 1993 to 2008. Am J Prev Med. 2010 Sep;39(3):220-7. doi: 10.1016/j.amepre.2010.03.026. PubMed 20709253 ↗
  • Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2021 Apr;39(2):208-221. doi: 10.5534/wjmh.200010. Epub 2020 Mar 9. PubMed 32202085 ↗
  • Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013 Sep;78(3):530-5. doi: 10.1016/j.gie.2013.04.197. Epub 2013 May 24. PubMed 23711556 ↗
  • Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: Results of a prospective study. Obesity (Silver Spring). 2016 Sep;24(9):1849-53. doi: 10.1002/oby.21555. Epub 2016 Jul 28. PubMed 27465076 ↗
  • Abu Dayyeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, Gostout CJ. Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. Clin Gastroenterol Hepatol. 2017 Jan;15(1):37-43.e1. doi: 10.1016/j.cgh.2015.12.030. Epub 2015 Dec 31. PubMed 26748219 ↗
  • Goyal RK, Guo Y, Mashimo H. Advances in the physiology of gastric emptying. Neurogastroenterol Motil. 2019 Apr;31(4):e13546. doi: 10.1111/nmo.13546. Epub 2019 Feb 10. PubMed 30740834 ↗
  • Aghaie Meybodi M, Qumseya BJ, Shakoor D, Lobner K, Vosoughi K, Ichkhanian Y, Khashab MA. Efficacy and feasibility of G-POEM in management of patients with refractory gastroparesis: a systematic review and meta-analysis. Endosc Int Open. 2019 Mar;7(3):E322-E329. doi: 10.1055/a-0812-1458. Epub 2019 Feb 28. PubMed 30842971 ↗
  • Mohan BP, Chandan S, Jha LK, Khan SR, Kotagiri R, Kassab LL, Ravikumar NPG, Bhogal N, Chandan OC, Bhat I, Hewlett AT, Jacques J, Ponnada S, Asokkumar R, Adler DG. Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. Surg Endosc. 2020 Aug;34(8):3352-3367. doi: 10.1007/s00464-019-07135-9. Epub 2019 Oct 3. PubMed 31583465 ↗

Individual participant data

Plan to share: No — As this is a pilot study to collect data for a larger NIH grant submission, we do not have plans to share data at this time.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 39 months is below that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Feb 3, 2023
StartActual
Sep 22, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05711758
Lead sponsor
Christopher C. Thompson, MD, MSc
Responsible party
Christopher C. Thompson, MD, MSc (Director of Endoscopy, Brigham and Women's Hospital) — Sponsor-investigator
First posted
Feb 3, 2023
Start date
Sep 22, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Michele B. Ryan, MS
Contact
mryan@bwh.harvard.edu
6176765928
Christopher C. Thompson, MD, MSc
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion